clinical trial · NCT05532735
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
Retinal Vein OcclusionANXV
brief summary
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
started
Aug 24, 2022
primary completion
Jul 17, 2024
completion
Nov 11, 2024
last updated
Dec 11, 2024
official title
Open-label, Dose Ascending Safety, Tolerability, and Proof of Concept Study to Evaluate the Use of ANXV (Human Recombinant Annexin A5) in the Treatment of Subjects With Recently Diagnosed Retinal Vein Occlusion
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol